Laurus Labs ' Nomination and Remuneration Committee has approved a comprehensive stock option grant across three Employee Stock Option Plans (ESOP), benefiting over 1,100 employees. The committee meeting held on January 23, 2026, sanctioned the distribution of 4,23,125 stock options at a uniform grant price of ₹754.50 per option.

Grant Distribution Across ESOP Schemes

The stock option allocation spans three distinct schemes with varying employee coverage:

Pricing and Effective Date

All options carry a face value of ₹2.00 each and are priced at ₹754.50 per option. This pricing represents a 25% discount to the market value of shares on the last trading day, January 22, 2026. The effective date for all grants is July 01, 2025, providing employees with participation in the company's performance through equity ownership.

Vesting Schedules

The vesting structure differs between the schemes. For the 2016 and 2018 ESOP schemes, options vest in three stages:

The 2021 ESOP scheme follows a four-stage vesting schedule with equal 25% distributions over five years, extending the final vesting to July 01, 2030.

Exercise Terms and Conditions

Employees must exercise their vested options within one year of the respective vesting dates. Options that remain unexercised beyond this period will lapse automatically. Each option, when exercised, converts into one fully paid-up equity share with a face value of ₹2.00.

The shares arising from option conversion will rank equally with existing equity shares and will not be subject to lock-in restrictions, except those imposed by applicable laws. This structure allows employees to participate directly in the company's growth while maintaining flexibility in their investment decisions.

Laurus Labs Limited witnessed a substantial block trade on the National Stock Exchange (NSE), marking a significant institutional transaction in the pharmaceutical sector. The block deal involved a considerable volume of shares at a premium price point, reflecting active institutional participation in the stock.

Block Trade Details

The transaction involved key parameters that highlight the scale and pricing of this institutional deal:

Transaction Significance

Block trades typically represent large institutional transactions that are executed outside the regular market mechanism to minimize market impact. The execution price of ₹1,064.70 per share for this transaction indicates the level at which institutional investors were willing to transact in Laurus Labs shares.

The transaction value of ₹15.41 crores represents a substantial deal size, suggesting significant institutional interest in the pharmaceutical company's equity. Such block trades often involve mutual funds, insurance companies, foreign institutional investors, or other large institutional participants.

Market Implications

Block trades of this magnitude often serve as indicators of institutional sentiment toward a particular stock. The successful execution of this transaction at the specified price level demonstrates liquidity availability in Laurus Labs shares at current market levels.

The pharmaceutical sector has been witnessing active institutional participation, and this block trade adds to the overall transaction activity in the sector. Such institutional transactions typically reflect long-term investment strategies rather than short-term trading positions.